Progenics Pharmaceuticals (PGNX)
Add to Watchlists Create an AlertProgenics Pharmaceuticals Enterprise Value:
141.09M for May 23, 2013Progenics Pharmaceuticals Historical Enterprise Value Data
Pro Data ExportThere is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| May 23, 2013 | 141.09M |
| May 22, 2013 | 141.09M |
| May 21, 2013 | 146.71M |
| May 20, 2013 | 154.38M |
| May 17, 2013 | 161.54M |
| May 16, 2013 | 152.33M |
| May 15, 2013 | 148.76M |
| May 14, 2013 | 154.89M |
| May 13, 2013 | 171.25M |
| May 10, 2013 | 168.70M |
| May 9, 2013 | 161.03M |
| May 8, 2013 | 169.72M |
| May 7, 2013 | 165.12M |
| May 6, 2013 | 162.05M |
| May 3, 2013 | 163.58M |
| May 2, 2013 | 163.07M |
| May 1, 2013 | 144.15M |
| April 30, 2013 | 176.37M |
| April 29, 2013 | 173.30M |
| April 26, 2013 | 186.59M |
| April 25, 2013 | 195.28M |
| April 24, 2013 | 191.19M |
| April 23, 2013 | 187.61M |
| April 22, 2013 | 186.59M |
| April 19, 2013 | 183.52M |
| April 18, 2013 | 181.48M |
| April 17, 2013 | 175.34M |
| April 16, 2013 | 183.52M |
| April 15, 2013 | 177.90M |
| April 12, 2013 | 191.19M |
| April 11, 2013 | 194.26M |
| April 10, 2013 | 197.59M |
| April 9, 2013 | 199.38M |
| April 8, 2013 | 196.82M |
| April 5, 2013 | 197.33M |
| April 4, 2013 | 198.35M |
| April 3, 2013 | 193.24M |
| April 2, 2013 | 217.27M |
| April 1, 2013 | 209.60M |
| March 28, 2013 | 216.25M |
| March 27, 2013 | 216.76M |
| March 26, 2013 | 223.92M |
| March 25, 2013 | 203.98M |
| March 22, 2013 | 201.42M |
| March 21, 2013 | 200.91M |
| March 20, 2013 | 195.80M |
| March 19, 2013 | 181.99M |
| March 18, 2013 | 171.25M |
| March 15, 2013 | 164.09M |
| March 14, 2013 | 113.99M |
About Enterprise Value
Click "Learn More" below to see how YCharts calculates Enterprise Value.
Enterprise Value (EV) is a valuation metric alternative to traditional market capitalization that reflects the market value of an entire business. Like market cap, EV is a measure of what the market believes a company is worth. Enterprise value captures the cost of an entire business, including debt and equity. It is a sum of claims of all preferred shareholders, debt holders, security holders, common equity holders, and minority shareholders - unlike market cap, which only captures the total value of common equity securities.
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Learn More
PGNX Enterprise Value Benchmarks
| Companies | |
|---|---|
| Salix Pharmaceuticals | 3.664B |
| Sequenom | 318.74M |
| Santarus | 1.402B |
PGNX Enterprise Value Rankings
| Overall |
57th percentile 3441 of 8006 |
| Sector |
47th percentile 357 of 686 in Healthcare |
| Industry |
57th percentile 105 of 248 in Biotechnology |
PGNX Enterprise Value Range, Past 5 Years
| Minimum | 9.441M | Nov 11 2009 |
| Maximum | 426.65M | Jun 16 2008 |
| Average | 138.79M |
